PACE: Analysis of acute toxicity in PACE-B, an international phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) to conventionally fractionated or moderately hypofractionated external beam radiotherapy (CFMHRT) for locali

Nicholas John Van As

A randomized trial comparing fluorocholine-PET/CT with conventional imaging in prostate cancer.

Scott Williams

SABR in high-risk prostate cancer: Outcomes from two prospective clinical trials with and without elective nodal irradiation.

Yasir Alayed

Time to PSA nadir and the risk of death from prostate cancer following radiation and androgen deprivation therapy.

Luke Roy George Pike

Rectal toxicity results for patients treated with HDR brachytherapy as monotherapy versus dose-escalated external beam radiotherapy for localized prostate cancer.

Jacob Samuel Parzen

Active surveillance and watchful waiting for low-risk prostate cancer in black patients: A population-based analysis.

Santino Butler

“Management Migration” in United States patients diagnosed with localized prostate cancer from 2010-2015.

Santino Butler

Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database.

Amandeep R Mahal

Management of low-risk prostate cancer in a population-based cohort of Australian men between 2008 and 2016.

Wee Loon Ong

Prospective head-to-head comparison of 18F-fluciclovine and 68Ga-PSMA-11 PET/CT for localization of prostate cancer biochemical recurrence after primary prostatectomy.

Jeremie Calais

Second cancer following radical prostate cancer treatment.

Bjorg Yksnoy Aksnessaether

Genomic validation of three-tiered sub-classification of high-risk prostate cancer.

Vinayak Muralidhar

GATA2 exosomal mRNA: A novel urine biomarker for the diagnosis of clinically significant prostate cancer.

Jungreem Woo

Are prostate cancer patients with BRCA1 and BRCA2 mutations safe for active surveillance?

Marc Dall'era

Outcomes of the patients with pT0 on first protocol biopsy during active surveillance for early prostate cancer: From the PRIAS-JAPAN study.

Takuma Kato

External beam radiation therapy and brachytherapy boost versus radical prostatectomy and adjuvant radiation therapy for high-risk prostate cancer.

Vinayak Muralidhar

Direct evidence of a clonal and tumor-directed T cell response to prostate cancer brachytherapy.

Scott Williams

Radiation-related lymphopenia after pelvic nodal irradiation for prostate cancer.

Sunil W Dutta

Stereotactic body radiotherapy (SBRT) versus conventional fractionated intensity-modulated radiotherapy (CF-IMRT) for patients with early-stage localized prostate cancer: One-year late toxicity results from a prospective randomized phase II study.

Darren M.C. Poon

The effect of the timing of biochemical failure after external beam radiotherapy or low-dose-rate brachytherapy for definitive prostate cancer treatment.

Jay P. Ciezki

Phase II trial enzalutamide and androgen deprivation therapy (ADT) with salvage radiation in men with high-risk PSA recurrent prostate cancer (PC): The STREAM trial.

Andrew J. Armstrong

SelectMDx versus Prostate Health Index in the identification of high-grade prostate cancer.

Gretchen Hoyer

Multi-institutional analysis of synchronous prostate and rectosigmoid cancers.

Corbin Jacobs

Impact of compliance on outcomes for patients on active surveillance for prostate cancer.

Jay Detsky

Do elderly men (>75) harbor more aggressive prostate cancer? Comparison of decipher and PAM50 TESTS among different age groups.

Hanan Goldberg

Long-term follow-up after radiotherapy for prostate cancer with and without rectal hydrogel spacer: A pooled prospective evaluation of quality of life.

Zachary Seymour

Impact of putative chemopreventative agents on prostate cancer diagnosis.

Hanan Goldberg

Prostate cancer-related quality of life and risk for anxiety and depression.

Shauna McManus

Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN trial.

Felix Y Feng

Validation and physiological association of changes in magnetic resonance imaging radiomic features in response to androgen deprivation therapy in patients with high-risk prostate cancer.

Hannah Tharmalingam

Does tumor location affect prostate cancer prognosis?

Jun Akatsuka

The impact of intratumoral heterogeneity on prognostic biomarkers in localized prostate cancer.

Harry Brastianos

The predictive value of DRE in the modern era of prostate cancer diagnostics.

Joel Marcus Andersson

Multi-institutional analysis of high-risk prostate cancer patients treated with stereotactic body radiotherapy.

Naomi Y Jiang

Early predicting factor for biochemical failure for patients with intermediate and high-risk prostate cancer treated by definitive radiotherapy.

Hye Jin Kang

Genomic analysis and clinical outcomes of Primary Gleason Pattern 5 (PG5) prostate cancer (PCa) treated with radical prostatectomy (RP).

Pedro Isaacsson Velho

Inflammatory bowel disease and risk of prostate cancer: A matched-cohort analysis.

Adam Weiner

Molecular characterization of longitudinally tracked prostate cancer foci in men on active surveillance for low risk disease.

Jeffrey J. Tosoian

A multibiomarker approach to predict prostate cancer pathology outcomes.

Pamela Paris

Hypofractionated dose painting IMRT using 20 fractions for intermediate to high risk localised prostate cancer: Two-year outcome data (BIOPROP20, NCT02125175).

Isabel Syndikus

A phase I pilot study of preoperative radiotherapy for prostate cancer: Long-term toxicity and oncologic outcomes.

Noelia Sanmamed

Activity of NEO2734, a novel dual inhibitor of both BET and CBP-P300, in SPOP-mutated prostate cancer.

Yuqian Yan

A study of intense neoadjuvant testosterone lowering therapy with goserelin and enzalutamide (Enza) in high-risk prostate cancer (PC) with multiparametric MRI (mpMRI).

Fatima Karzai

Predictors of prostate cancer-specific anxiety following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer.

Kamran Salari

Cost implications of multi-parametric magnetic resonance imaging in prostate cancer active surveillance.

Michelle Yu

Management of isolated local failures following stereotactic body radiation therapy for low to intermediate risk prostate cancer.

Nicolette Drescher

Ten year treatment complication outcomes of radical prostatectomy versus external beam radiation therapy versus brachytherapy for 1,503 patients with intermediate risk prostate cancer.

Barry W. Goy

Is there a correlation between Gleason score and maximum standardized uptake value in locally advanced prostate cancer patients?

Onal Cem

Role of magnetic resonance imaging-transrectal ultrasound fusion targeted biopsy in the detection of prostate cancer in biopsy-naïve men: A literature based meta-analysis of randomized trials.

Xiang Tu

Correlation between PSA kinetics and detection rate of PSMA-PET in the setting of biochemical recurrent prostate cancer: A systematic review and meta-analysis.

Ricardo Pereira Mestre

Racial disparities in survivorship care adherence among Medicare beneficiaries with prostate cancer.

Ravi Bharat Parikh

MiR-34a to enhance the radiosensitivity of 22RV1 and 22RV1-radiation resistance prostate cancer cell lines.

John Thoms

Cascade testing of men with prostate cancer in families with a spectrum of inherited cancers: Importance of attention to race.

Veda N. Giri

Providers’ inability to estimate health literacy among African American (AA) patients (pts) with early prostate cancer (PCa).

William Martin-Doyle

Moderately hypofractionated radiotherapy for localized prostate cancer: Long-term outcomes for 854 consecutive patients treated over 10 years (70 Gy in 2.5 Gy/fraction).

Omar Y. Mian

Four-year outcomes of hypofractionated proton therapy for localized prostate cancer.

Amardeep S. Grewal

The molecular hallmarks and clinical consequences of tumor hypoxia in prostate cancer.

Bhandari Vinayak

Machine learning approaches to improve prostate cancer outcome.

Ronnie Rodrigues Pereira

Evaluating non-hormonal therapy in a phase II trial of SM-88 for rising PSA prostate cancer.

Benjamin Adam Gartrell

Health literacy is a barrier to shared decision making in early prostate cancer (PCA) among African American (AA) men.

William Martin-Doyle

Immune infiltrate with CD8 low or PDL1 high associated with metastatic prostate cancer after radical prostatectomy (RP).

Cecile Vicier

Prospective evaluation of a new patient decision aid to enhance prostate cancer screening decision-making.

Michael Austin Brooks

Cribriform pattern, Genomic Prostate Score, and adverse pathology at radical prostatectomy in a cohort of prostate cancer patients initially on active surveillance.

Kyle Brian Zuniga

Outcomes of active surveillance for African-American men with prostate cancer: Results of a matched analysis.

Lewis Thomas

Cost-effectiveness of a two-gene urine biomarker assay in MRI strategies for the initial detection of prostate cancer.

Tim Govers

Trends in complementary and alternative medicine use among newly diagnosed prostate cancer patients.

Kyle Brian Zuniga

Clinical utility study of confirms mdx for prostate cancer in a community urology practice.

Paul Yonover

Clinical and genetic determinants of toxicity and quality-of-life (QOL) outcomes for SBRT in Asian prostate cancer.

Janice Ser Huey Tan

Validation of a two-gene mRNA urine test for detection of high-grade prostate cancer in German men.

Derya Tilki

Preoperative trial of neoadjuvant abiraterone plus or minus cabazitaxel: Early results.

Jaime Omar Herrera-Caceres

Impact of testosterone replacement therapy after radiation therapy on prostate cancer outcomes.

Reith Sarkar

Impact of testosterone replacement therapy after radical prostatectomy on prostate cancer outcomes.

Reith Sarkar

Efficacy and toxicity from phase II study of dose escalation to intraprostatic tumor nodule in localized prostate cancer.

Julia Murray

One and done?: Utility of PSA density as a predictor of number of cores needed to detect clinically significant prostate cancer.

Graham Hale

Brachytherapy use for favorable-risk prostate cancer continues to decline in both academic and community centers despite superior survival compared to dose-escalated external beam radiation therapy.

Kevin H. Nguyen

MRI targeted biopsy dramatically increases detection of clinically significant prostate cancer while reducing the risk of indolent cancer detection.

Michael Ahdoot

Optimizing the use of androgen deprivation therapy in men with localized intermediate risk prostate cancer in the era of modern dose-escalated radiation therapy.

Sagar Anil Patel

MRI-TRUS fusion-guided biopsy in obese patients: Does it reduce risk of prostate cancer upgrade on final pathology compared to systematic 12-core biopsy?

Samuel A Gold

Incidence and pathological features of metachronous bladder cancer in prostate cancer patients treated with brachytherapy or radical prostatectomy in a single institution.

Kotaro Obayashi

The impact of Charlson Comorbidity Index on survival outcomes in men with prostate cancer who underwent definitive prostate radiotherapy.

Ahmed I. Ghanem

Racial disparities in late-stage prostate cancer: A SEER database analysis 2005–2015.

Jianqing Lin

The cost of prostate cancer care to society and to patients in the United States.

Nicholas George Zaorsky

Overall survival outcomes with the use of adjuvant chemotherapy, radiation therapy and hormone therapy in high-risk, very-high-risk and node-positive prostate cancer post radical prostatectomy: A NCDB analysis.

Alina Basnet

State rurality does not increase risk of prostate cancer death.

Alexander Geoffrey Shaw Anderson

Racial differences in long-term prostate cancer specific mortality following conservative management for low-risk prostate cancer: A population-based study.

Grace L. Lu-Yao

Intraductal carcinoma of the prostate in prostate biopsy samples: Correlation with pathological features after radical prostatectomy and prognostic value in high-risk prostate cancer patients.

Sha Zhu

Increasing utilization of multi-parametric magnetic resonance imaging in prostate cancer active surveillance.

Avinash Maganty

Radiogenomic characterization of multifocal prostate cancer.

Simpa Samuel Salami

The value of transperineal prostate apical zone biopsy in predicting urethral or apical margin status after radical prostatectomy in prostate cancer.

Jindong Dai

The validation of the 2014 International Society of Urological Pathology (ISUP) grading system for patients with high-risk prostate cancer: A single-center retrospective study.

Jiandong Liu

Marijuana use history in patients presenting with localized prostate cancer.

Romaine Charles Nichols

Reduced risk of prostate cancer in a cohort of Lithuanian diabetes mellitus patients.

Ausvydas Patasius

Late toxicity described using patient reported outcomes measures (PROMS) in men treated with salvage radiation following primary high intensity focal ultrasound (HIFU) for localized prostate cancer.

Reena Davda

Prostate cancer in young men: Our experience.

Joao Vasco Barreira

Experience of a single Brazilian center on PSMA-PET in biochemical recurrence in patients with prostate cancer.

Paulo Sergio Lages

Incidence of hypocalcemia in patients with castration-resistant prostate cancer treated with denosumab: Data from a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab administered every four weeks (q4w

Silke Gillessen

ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC).

Karim Fizazi

Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT).

Karim Fizazi

Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).

Padmanee Sharma

Assessment of circulating tumor cell number as a transitional surrogate endpoint for survival in phase II trials for metastatic castration-resistant prostate cancer.

Howard I. Scher

Updated analysis of progression-free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamide (APA) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC).

Eric Jay Small

Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).

Evan Y. Yu

Genomic drivers of poor prognosis and enzalutamide resistance in metastatic castration-resistant prostate cancer.

William S. Chen

Cost-effectiveness of metastasis-directed therapy in the setting of oligometastatic hormone-sensitive prostate cancer.

Neil Rohit Parikh

A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study.

Orazio Caffo

Late administration of luteinizing hormone-releasing hormone (LHRH) agonists and the impact on testosterone suppression in the real-world management of prostate cancer.

Przemyslaw Twardowski

Efficacy of docetaxel and androgen receptor axis-targeted agents in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate.

Akiyuki Yamamoto, None

Measurement science of the androgen receptor splice variant-7 protein in primary and castration-resistant prostate cancer tissue.

Adam Sharp

Targeting mediator subunits CDK8/CDK19 for treatment of advanced prostate cancer.

Marie C. Hupe

Quality of life differences for LHRH-antagonist versus LHRH-agonist in special patient groups with cardiovascular comorbidities and higher tumor burden in patients with hormone-sensitive prostate cancer (hsPCa).

Jan Lehmann

Response to PARP inhibitor therapy in metastatic castrate-resistant prostate cancer (mCRPC) patients with BRCA1/2 versus ATM mutations.

Catherine Handy Marshall

Outcome, costs and dollar value of docetaxel and abiraterone in prostate cancer.

Helmy M. Guirgis

A circulating tumor cell RNA assay for dynamic assessment of androgen receptor signaling inhibitors sensitivity in metastatic castration-resistant prostate cancer.

Yu Jen Jan

Low incidence of microsurges with biodegradable polymer-delivered, subcutaneously-administered leuprolide acetate in prostate cancer patients.

Eleni Efstathiou

Predictors of germline DNA damage repair gene mutations (gDDRm) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).

Steven Yip

A Genome-wide association study of metastatic prostate cancer.

Craig Teerlink

A retrospective observational study assessing bone metastases (mets) detection and management of patients (pts) with castration-resistant prostate cancer (CRPC) in Canada.

Fred Saad, MD

Prostate cancer cost-of-care and evaluation of traditional cost control measures.

Dhruv Bansal

A phase II, open-label, multi-arm study of TAS-115 for castration-resistant prostate cancer patients with bone metastases.

Hiroji Uemura,

Impact of the USPSTF recommendations on prostate cancer stage migration and de-novo metastatic prostate cancer.

Yu-Wei Chen

The effect of VERU-111, a novel oral inhibitor of α and β tubulin, on tumor growth in the human castration-resistant, AR-variant prostate cancer (PCa) model 22Rv1.

Mark Christopher Markowski

Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: A multicenter randomized phase II trial (OCUU-CRPC study).

Taro Iguchi

A phase I/II study of proxalutamide (GT0918), a potent androgen receptor blocker, in patients with mCRPC progressed after both hormonal therapy and chemotherapy.

Nicholas J. Vogelzang

Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).

Christophe Massard

Keynote-365 cohort C: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).

Peter C.C. Fong

Pembrolizumab in men with heavily treated metastatic castration-resistant prostate cancer (mCRPC).

Matthew D Tucker

A phase I and randomized phase II study of cabozantinib plus docetaxel and prednisone (C+DP) versus docetaxel and prednisone (DP) alone in metastatic castrate-resistant prostate cancer (mCRPC).

Munjid Al Harthy

Experience with sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC) with visceral spread from PROCEED.

Nicholas J. Vogelzang

Associations of cell cycle genetic variants with aggressive prostate cancer in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

Melissa Huynh

In geriatric evaluation, some iadl (Katz) scale items are more predictive of efficacy and toxicity than ADL (Lawton) scale or Charlson Comorbidity Index in metastasic castration-resistant protate cancer (mCRPC) patients treated with cabazitaxel in a weekl

Miguel Ángel Climent

Real-world PROCEED registry data: Sipuleucel-T in elderly men with metastatic castration-resistant prostate cancer (mCRPC).

Andrew J. Armstrong

Age-related variation in gene alteration frequency in metastatic prostate cancer.

Zachary Rockow Chalmers

A noninvasive prognostic biomarker for metastatic castration-resistant prostate cancer: Very small nuclear circulating tumor cells.

Pin-Jung Chen

A retrospective analysis of treatment patterns in metastatic castration-resistant prostate cancer patients treated with radium-223.

A. Oliver Sartor

A genetic risk score to personalize prostate cancer screening, applied to population data.

Minh-Phuong Huynh-Le

CCN3/NOV as a functional driver and prognostic biomarker of prostate cancer bone metastasis.

Veronique Ouellet

The clinical impact of bone scan (BS) flare with enzalutamide (ENZA) in men with metastatic castration-resistant prostate cancer (mCRPC).

Andrew J. Armstrong

Characterization of PSA at death in patients with metastatic castration-resistant prostate cancer.

Krishna Bikkasani

A phase III, randomized, double-blind, placebo-controlled study of enzalutamide in men with nonmetastatic castration-resistant prostate cancer: Post-hoc analysis of PROSPER by prior therapy.

Ugo De Giorgi

Clinical outcomes in Caucasian (C), African American (AA) and Asian men with metastatic castration-resistant prostate cancer (mCRPC).

Susan Halabi

Docetaxel in older patients for metastatic prostate cancer.

Frances May Mark

Whole blood FOLH1 mRNA expression and treatment response in metastatic castration-resistant prostate cancer (mCRPC).

Edmond Michael Kwan

Clinical progression at initiation of a life-extending therapy (LET) in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis, whatever the treatment-line: Results of the CATS retrospective registry.

Nicolas Delanoy

Determining androgen inactivation status in prostate cancer by [18F] DHT PET.

Ziqi Zhu

Outcomes of high-dose whole pelvic simultaneous integrated boost IMRT in patients with pelvic lymph node-positive prostate cancer.

Takashi Mizowaki

The Veterans Health Administration Precision Oncology Program for Advanced Prostate Cancer Patients: Expanding tumor NGS opportunities to a broader patient population.

Alexandra Sokolova

Next Generation Sequencing (NGS) in metastatic castration resistant prostate cancer (mCRPC) to identify targets for individualized treatment: Is it feasible in daily routine?

Axel Heidenreich

Identification, incidence and clinical outcomes of patients (pts) with hypermutated prostate cancer (PC).

Simon Yuen Fai Fu

Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with metastatic castration-resistant prostate cancer (mCRPC).

Jingsong Zhang

Treatment efficacy of abiraterone (abi), enzalutamide (enza) or cabazitaxel (caba) in metastasic castration resistant prostate cancer patients (mCRPC) after progression to docetaxel plus androgen deprivation therapy (ADT) in hormone sensible disease.

Miguel Ángel Climent

Genomic determinants of sensitivity to bipolar androgen therapy (BAT) in castrate-resistant prostate cancer (CRPC).

Michael Thomas Schweizer

Metastasis-free survival as a predictor of overall survival in non-metastatic castration-resistant prostate cancer.

Richard Gagnon

Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD.

Matthew Raymond Smith

Plasma AR status and cabazitaxel in heavily-treated metastatic castration-resistant prostate cancer (mCRPC).

Vincenza Conteduca

A multidisciplinary team-based approach to mitigate the impact of androgen deprivation therapy in prostate cancer: A randomized phase II study.

YaoYao Guan Pollock

Prostate cancer-derived anti-GRP78 autoantibodies compromise the blood-brain barrier and accelerate atherosclerosis progression in vivo.

Ali Al-Hashimi

Investigating a novel recombinant antibody to attenuate prostate cancer progression by targeting cell surface GRP78.

Ali Al-Hashimi

ARV7 and ARFL mRNA in blood to predict androgen receptor inhibitors and docetaxel response in castration-resistant prostate cancer patients.

Mercedes Marin

The efficacy of enzalutamide for castration-resistant prostate cancer (CRPC) patients with intraductal carcinoma of the prostate (IDC-P).

Hideji Kawanishi

Genomic characterization of pulmonary-metastatic prostate cancer: A unique molecular subtype.

Eugene Shenderov,

Impact of prostate specific antigen doubling time on time to metastasis and overall survival in non-metastatic castration-resistant prostate cancer patients.

Stephen J. Freedland

Overall survival by race in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide.

Megan Ann McNamara

Final analysis of a phase II study of MRI based functional imaging of bone metastases in men with metastatic castrate-resistant prostate cancer (mCRPC) receiving Cabozantinib.

Arpita Desai

Positron emission tomography with 18F-fluciclovine to predict recurrence in post-treatment recurrent prostate cancer and its role in altering treatment plans.

Julio Chong

An updated analysis evaluating skeletal related events (SREs) in CTRIAL-IE 13-21: Phase II trial of radium-223 (R223) in combination with enzalutamide (ENZA) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

John Patrick Greene

Pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Updated analysis of KEYNOTE-199.

Emmanuel S. Antonarakis

Immunogenomic landscape of neuroendocrine small cell prostate cancer.

Lucia Nappi

Circulating tumor (ct) DNA-based genomic profile of prostate cancer (PCa) patients with elevated carcinoembryonic antigen (CEA).

Pannaga G. Malalur

Quality-of-life (QoL) assessment and reporting in prostate cancer: A systematic review of phase III trials published between 2012 and 2016.

Laura Marandino

Next generation N-terminal domain androgen receptor inhibitors with improved potency and metabolic stability in castration-resistant prostate cancer models.

Ronan Le Moigne

The role of enzalutamide-induced hyperactive Jak2-Stat5 feed-forward signaling loop on enzalutamide-resistant prostate cancer growth and as a therapeutic target for second-line treatment.

Vindhya Udhane

Interpreting survival outcomes for African-American (AA) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with sipuleucel-T (SIP-T) with number needed to treat to benefit (NNTB).

Kelvin A. Moses

Radium 223 treatment in metastatic castrate-resistant prostate cancer: Impact of sequencing on survival—Real-world outcomes from a single UK centre.

Xue Yan Jiang

Immunogenomic landscape of Neuroendocrine Prostate Cancer (NEPC).

Alison Ferguson

Morphology-predicted, large-scale transition (LST) number in circulating tumor cells (CTC) as a biomarker of chromosomal instability (CIN) to assess early resistance to standard of care (SOC) drugs in mCRPC.

Howard I. Scher

Discovery of targetable mutational signatures in advanced prostate cancer (aPC) using machine learning and next-generation sequencing (NGS) of circulating tumor DNA (ctDNA).

Edwin Lin

Clinicopathologic and genomic characterization of parenchymal brain metastases (BM) in prostate cancer (PCa).

Jose Mauricio Mota

Results of a 50 patient single-centre phase II prospective trial of Lutetium-177 PSMA-617 theranostics in metastatic castrate-resistant prostate cancer.

Michael Hofman

Tumor testing in men with prostate cancer to predict for germline DNA-damage repair mutations.

Maria Isabel Carlo

Clinical validation of circulating cytokines as markers of prognosis and response to docetaxel in men with metastatic castration-resistant prostate cancer.

Kate Lynette Mahon

Early 18F-FDHT PET/CT as a predictor of treatment response in mCRPC treated with enzalutamide.

Hilde Hoving

Association between urinary, bowel, and hormonal treatment-related symptoms and clinical outcomes in nonmetastatic castration-resistant prostate cancer (nmCRPC): PROSPER study.

Fred Saad

Health-related quality of life (HRQoL) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib in combination with abiraterone.

Noel W. Clarke

The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as a biomarker of taxane resistance in castration-resistant prostate cancer.

Oscar Reig

Clinical events associated with cumulative corticosteroid use in patients with castration-resistant prostate cancer: An administrative claims analysis.

Benjamin H Lowentritt

Adverse events of special interest assessed by review of safety data in enzalutamide castration-resistant prostate cancer (CRPC) trials.

Bertrand F. Tombal

Cell plasticity associated to taxane-resistance in preclinical cell models and in circulating tumor cells from metastatic castration-resistant prostate cancer patients.

Ruth Montalbo

Risk of subsequent dementia from androgen deprivation therapy (ADT) versus orchiectomy among men with prostate cancer.

Ravi Bharat Parikh

Methylation-associated miR193b silencing activates master drivers of aggressive prostate cancer.

Ying Zhang Mazzu

Efficacy of abiraterone and enzalutamide in patients who had disease progression within twelve months of completing docetaxel for metastatic castration sensitive prostate cancer.

Gang Chen

Plasma cell-free DNA-based prognosis in metastatic hormone sensitive prostate cancer.

Manish Kohli

The effect of a structured exercise intervention on CTCs and platelet cloaking in patients with metastatic prostate cancer.

Lauren Brady

Impact of new systemic therapies on outcomes of patients with non-metastatic castration resistant prostate cancer (nmCRPC).

Cecile Vicier

DNA repair germline pathogenic mutation associations with treatment duration and family history in prostate cancer.

James Vu

Aberrations in androgen receptor ctDNA varies by race in metastatic castrate-resistant prostate cancer.

Bryce Raymon Christensen

Identification of bone involvement in patients with prostate cancer recurrence using 18F-fluciclovine PET/CT and impact on subsequent management.

Michael S Kipper

TP53 mutations in circulating tumor DNA in men with metastastic castration-resistant prostate cancer mCRPC.

Lynne Chapman

Preliminary results of a two stage phase II study of 18F-DCFPyL PET-MR for enabling oligometastases ablative therapy in subclinical prostate cancer.

Rachel Glicksman

The tumor immune microenvironment differs between metastatic castrate resistant prostate cancer (CRPC) and hormone sensitive prostate cancer (HSPC).

Kobe Chi Yung Yuen

Clinical characteristics of men with prostate cancer and evaluation of NCCN prostate cancer guidelines on germline genetic testing outcomes.

Samantha Greenberg

Clinical outcome with concurrent or layered treatment with radium-223 and abiraterone: A retrospective study of real-world experience with patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Daniel J. George

Evaluation of circulating tumor DNA (ctDNA) with respect to germline alterations in metastatic castrate resistant prostate cancer patients.

Peter Steinwald

Pembrolizumab (pembro) in heavily pretreated metastatic castrate-resistant prostate cancer (mCRPC).

Marcus Marie Moses

Treatment patterns and outcomes for metastatic castration-resistant prostate cancer (mCRPC) in a real-world setting: A retrospective study of greater than 2500 patients.

Celestia S. Higano

Lessons learned from the metastatic castration-resistant prostate cancer phase I trial of EPI-506, a first-generation androgen receptor N-terminal domain inhibitor.

Ronan Le Moigne

Germline DNA repair mutations in men with prostate cancer are less frequent in African Americans as compared with Caucasians.

Piper L.W. Nicolosi

ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.

Taavi Neklesa

First-in-field small molecule inhibitors targeting BRN2 as a therapeutic strategy for small cell prostate cancer.

Daksh L. Thaper

Performance of the 17-gene genomic prostate score test in men with prostate cancer (PCa) managed with active surveillance (AS): Results from the Canary Prostate Active Surveillance Study (PASS).

Daniel W. Lin

Apalutamide (APA) or enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (CRPC): A systematic review and network meta-analysis of randomized clinical trials (RCTs).

Irbaz Bin Riaz

Impact of treatment sequence in metastatic castration-resistant prostate cancer (mCRPC) on outcome in a prospective cohort study.

Rebeca Lozano

ctDNA and copy-number variant quantification in mCRPC at the time of progression.

Patrick Cotogno

Neutrophil-to-lymphocyte ratio as a prognostic biomarker for overall survival in men with advanced prostate cancer treated with platinum chemotherapy.

Panagiotis J. Vlachostergios

Assessing the real-world (RW) efficacy and toxicity of docetaxel (D) for the treatment of metastatic castrate sensitive prostate cancer (mCSPC): A single institution experience.

Seanthel Delos Santos

Sipuleucel-T to modify the B7-H3 immune checkpoint in men with castrate resistant prostate cancer.

Wei Phin Tan

Treatment facility volume and survival in patients with advanced prostate cancer.

Shreyas Joshi

EphB4-EphrinB2 receptor-ligand pair as a novel target in prostate cancer (PC).

Sarmad Sadeghi

Survival outcomes for adjuvant or salvage radiation in men with pN+M0 prostate cancer.

Jonathan David Tward

3βHSD1 immunohistochemistry and HSD3B1 genotype in prostate cancer.

JJ Haijing Zhang

Value of serum neuroendocrine markers in evaluation of neuroendocrine prostate cancer: A validation study using metastatic biopsies.

Panagiotis J. Vlachostergios

Plasma-based exploratory biomarker analysis to evaluate GT0918 in a phase I/II study in mCRPC patients.

Jianjun Yu

PEAX: Men with metastatic castrate-resistant prostate cancer (mCRPC) treated with either sipuleucel-T (SIP-T), enzalutamide (ENZA) or abiraterone acetate (ABI) undergoing cardiopulmonary exercise testing (CPET).

Michael Roger Harrison

Somatic alterations in a seven-gene DDR gene panel predicts platinum sensitivity in advanced prostate cancer patients.

Panagiotis J. Vlachostergios

Concomitant characterization of androgen receptor (AC) and immune checkpoints (ICs) in cell-free (cf) DNA and RNA from patients with metastatic castration resistant prostate cancer (mCRPC).

Sumanta K. Pal

Obesity and metastatic castration resistant prostate cancer: Results from the control arms of ASCENT2, MAINSAL and VENICE trials.

Alberto Martini

Utilization and outcomes of surgical castration in comparison to medical castration in metastatic prostate cancer.

Rohan Garje

German health service research with the focus on effectiveness of secondary-antiandrogen deprivation therapy (s-ADT) in prostate cancer patients with buserelin in daily practice.

Gerson Luedecke

Exploratory study of prognostic factors in mCRPC patients who administered enzalutamide focusing on early PSA decline and PSA kinetics at PSA progression: Results of retrospective multicenter study.

Yoshiyuki Miyazawa

Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: A retrospective study.

Kosuke Hamada

Alkaline phosphatase (ALP) value at diagnosis of CRPC and response to primary androgen deprivation therapy may predict metastasis in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC).

Mori Keiichiro

A survey to determine patients’ (pts) opinions of a clinical trial (CT) comparing intermittent (int) versus continuous (cont) androgen receptor signaling inhibitor (ARSi) therapy for the treatment of advanced prostate cancer.

Cameron Phillips

Effect of IL-6 and related mediators on resistance to abiraterone acetate (abi) and enzalutamide (enza) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Jacob J. Adashek

Timing of docetaxel chemotherapy and impact on outcomes in metastatic castrate-resistant prostate cancer (MCRPC).

Alastair Thomson

The oral α and β tubulin inhibitor, VERU-111, for the treatment of metastatic castration-resistant and androgen blocking agent-resistant prostate cancer in nonclinical toxicity studies.

Robert H. Getzenberg

Prognostic significance of lactate dehydrogenase-5 expression in patients with prostate cancer treated with androgen deprivation therapy and androgen receptor axis-targeted agents.

Wataru Fukuokaya

Preclinical evaluation of AMG 160, a next-generation bispecific T cell engager (BiTE) targeting the prostate-specific membrane antigen PSMA for metastatic castration-resistant prostate cancer (mCRPC).

Julie Bailis

The effect of androgen receptor splice variant 7 on the growth of castration-resistant prostate cancer and the efficacy of taxane chemotherapy.

Yasuomi Shimizu

Abiraterone acetate plus prednisone/prednisolone compared with enzalutamide in metastatic castration resistant prostate cancer before or after chemotherapy: A retrospective study of real-world data (ACES).

Prantik Das

Prostate cancer (PCa) incidence and severity in 821 hypogonadal men with and without testosterone therapy (TTh) in a controlled, observational registry implying more than 7,000 patient-years.

Ahmad Haider

Next generation sequencing of primary prostate cancer tumors to reveal potentially actionable opportunities for clinical management: The UNC experience.

Daniel James Crona

Biochemichal recurrence in prostate cancer after salvage surgery in correlation to the site of reccurrent disease.

David Pfister

Intermittent bicalutamide in recurrent non-metastatic castrate sensitive prostate cancer: A single institution experience.

Mark Prentice

The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.

Onal Cem

Patients with an extremely high prostate-specific antigen at prostate cancer diagnosis: A single institution analysis.

Qian Qin

PRINT: Prostate cancer intensive, non-cross reactive therapy for CRPC—Early observations of feasibility and efficacy.

Bobby Chi-Hung Liaw

Protection of prostate cancer cells from GSK-3β-induced oxidative stress by Il-8 through activating the mTOR signaling pathway.

Yi Sun

Integration of radium-223 dichloride (Xofigo) into clinical practice for the treatment of castration-resistant prostate cancer.

Catherine Mary Doyle

The value of AKR1C3 in predicting the therapeutic efficacy of abiraterone for patients with metastatic castration-resistant prostate cancer.

Jinge Zhao

Clinical significance of AR amplification from CF DNA among Japanese castration-resistant prostate cancer patients.

Shinichi Sakamoto

The association of PSA levels and survival outcomes in patients with chemotherapy-naïve, castration-resistant prostate cancer (CRPC) who were treated with androgen receptor signaling axis targeting agent (ARAT): A Japanese cohort study.

Tatsuya Shimomura

The outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.

Berna Yildirim

Regional variations in online education test performance for prostate cancer care.

Hamsa Jaganathan

Clinical drivers for imaging testing in nonmetastatic castration-resistant prostate cancer: May they be optimized?—Data of “IDENTIFICA” study.

Eduardo Useros RodrÃguez

Continuous infusion 5-fluorouracil (5FU) as a novel treatment for heavily pretreated prostate cancer patients: An update.

Charlotte Manogue

Genomic changes of AR in ctDNA prior to enzalutamide in men with mCRPC after abiraterone acetate.

Leta Ko

Germline heterozygous BLM mutations and prostate cancer risk.

Elisa Ledet

Genetic testing patterns for homologous recombination repair (HRR) alterations in patients with metastatic prostate cancer (mPC): An assessment at the University of Rochester (UR).

Kerry Schaffer, MD

Clinical outcomes of a Dutch prospective observational registry of metastatic castration resistant prostate cancer (mCRPC) patients treated with radium-223 (Ra-223).

Rebecca Louhanepessy

Retrospective review of 11C-choline detected thoracic lesions in prostate cancer.

Muneeb Rehman

Synergistic effects of the PARP inhibitor olaparib and pharmacological ascorbate in castration-resistant prostate cancer.

Nicolas Gordon

Phase 3 study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial.

Andrew J. Armstrong

Randomized phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].

Jeremie Calais

Preoperative radiotherapy for high-risk prostate cancer (PORT-PC) trial.

Himanshu Nagar

The “ProPSMA Study” clinical trial protocol: A prospective randomized multi-center study of the impact of Ga-68 PSMA PET/CT imaging for staging high risk prostate cancer prior to curative-intent surgery or radiotherapy.

Michael Hofman

A phase II trial in progress: Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer and a circulating tumor cell homologous recombination deficiency (HRD) phenotype or BRCA defects.

Simon Chowdhury

A randomized phase Ib/II study of nivolumab with or without BMS-986253 in combination with a short course of ADT in men with castration-sensitive prostate cancer (MAGIC-8).

Matthew Dallos

Design of phase Ib/II study of oral VERU-111, an α and β-tubulin inhibitor, for the treatment of metastatic castration- and androgen-blocking-agent-resistant prostate cancer.

Mark Christopher Markowski

Modulation of plasma lipidomic signature in metastatic castration-resistant prostate cancer (mCRPC).

Blossom Mak

TheraP: A randomized phase II trial of [177Lu]-PSMA-617 theranostic versus cabazitaxel in progressive metastatic castration-resistant prostate cancer.

Michael Hofman

Evaluating the clinical, environmental, genetic, and genomic profile of men with early-onset aggressive prostate cancer (PCa).

Ahmad Zarzour

ODENZA: A study of patient preference between ODM-201 (darolutamide) and enzalutamide in men with metastatic castrate-resistant prostate cancer (mCRPC).

Geraldine Martineau

ProSTAR: A phase Ib/II study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Mary-Ellen Taplin

A phase II study of onvansertib (PCM-075) in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer.

David Johnson Einstein

TALAPRO-2: A two-part, placebo-controlled phase III study of talazoparib (TALA) with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC).

Neeraj Agarwal

A phase II, dose finding, placebo-controlled, study of zuclomiphene citrate to amerliorate the frequency and severity of hot flashes caused by androgen deprivation in men with advanced prostate cancer.

Robert H. Getzenberg

Phase I/II dose-escalation trial of fractionated dose 177Lu-J591 plus 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC).

Scott T. Tagawa

PROPEL: A randomized, phase III trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).

Noel W. Clarke

A phase II study of nivolumab in patients with high-risk biochemically recurrent (BCR) prostate cancer (PCa).

David Johnson Einstein

TALAPRO-1: An open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair (DDR) defects and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on g

Johann S. De Bono

Genetic counseling processes and outcomes among prostate cancer patients (ProGen).

Donna Rachel Vatnick

A randomized phase II study comparing cabazitaxel/prednisone to cabazitaxel alone in docetaxel-pretreated men with metastatic castration resistant prostate cancer (mCRPC): The CABACARE trial.

Carlo Buonerba

Personalized use of metronomic cyclophosphamide for DNA repair deficient castration-resistant prostate cancer: A phase II trial.

Cameron Phillips

A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer.

Vivek Narayan

A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.

Michael J. Morris

Phase Ib (COSMIC-021) trial of cabozantinib (C) in urothelial carcinoma (UC) or C in combination with atezolizumab (A) in patients (pts) with UC, castrate resistant prostate cancer (CRPC) or renal cell carcinoma (RCC).

Sumanta K. Pal